news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

china economic net, beijing, september 26th. the pre-disclosure announcement of the controlling shareholder's share reduction released by yidoli (300381.sz) last night showed that the company recently received a "notice on share reduction plan" issued by the controlling shareholder zhuhai jindaidi investment co., ltd. (hereinafter referred to as "jindaidi investment").

jindaidi investment plans to reduce its holdings of yidoli shares by no more than 9,580,000 shares (i.e. no more than 2.00% of the company's total share capital after excluding shares in the company's special repurchase securities account) through block trading within 3 months after 15 trading days from the date of disclosure of the announcement (i.e. from october 24, 2024 to january 23, 2025).

currently, golden land investment holds 151,767,378 shares of yidoli, accounting for 31.67% of the company's total share capital after excluding the shares in the company's special repurchase securities account.

the reason for this share reduction is the shareholder's own financial needs, and the shares come from shares issued before the company's initial public offering.

according to yidoli's 2023 annual report, the actual controller of the company is chen shaomei, who served as the company's chairman and president from august 1991 to august 2022, and has served as the company's chairman since september 2022. chen shaomei holds 90% of the shares of jindadi investment.

yidoli went public on january 28, 2014, and raised funds five times, totaling 1.537 billion yuan. as of the close of september 25, 2024, yidoli's total market value was 2.906 billion yuan.

on january 8, 2014, the company, through the lead underwriter minsheng securities co., ltd. (hereinafter referred to as "minsheng securities"), approved by the china securities regulatory commission's "securities regulatory license [2014] no. 64" and the shenzhen stock exchange, issued 11.45 million rmb common (a) shares at a price of rmb 27.88 per share, including 6.8 million new shares issued by the company and 4.65 million shares sold by shareholders. the company raised a total of rmb 189.584 million, and after deducting various issuance expenses of rmb 23.2484 million, the net amount of funds raised was rmb 166.3356 million. the above funds were in place on january 22, 2014.

on february 27, 2015, the listed company issued 3,081,854 new shares at rmb 20.28 per share to the specific target cai xiaoru in a non-public offering, and raised matching funds for the asset purchase. the total matching funds raised were rmb 62.5 million, and after deducting the issuance fee of rmb 6 million, the actual net amount of funds raised was rmb 56.5 million. the above funds were in place on may 27, 2015.

on november 24, 2015, the company was approved by the china securities regulatory commission to issue 15,527,023 shares to huachuang yiduoli employee growth no. 32 directed asset management plan, elite times jiuying no. 1 fund, golden eagle wenshi junye flexible allocation no. 3 asset management plan and cai xiaoru in a non-public offering, with a par value of rmb 1 per share and an issue price of rmb 33.49 per share. the share payment was paid in rmb, totaling rmb 520 million. after deducting the underwriting and sponsorship fees, issuance registration fees and other transaction fees totaling rmb 16.3274 million, the net raised funds totaled rmb 503.6726 million. the above funds were in place on june 27, 2016.

on november 2, 2018, the china securities regulatory commission approved the public issuance of convertible corporate bonds by guangdong yiduoli biotechnology co., ltd. (zhengjian license [2018] no. 1625), and the company publicly issued convertible corporate bonds of rmb 664,967,700 with a term of 6 years. after deducting the underwriting and sponsorship fees and other expenses totaling rmb 20,353,500, the net raised funds totaled rmb 644,614,200. the above funds were in place on december 29, 2018.

on october 12, 2020, the china securities regulatory commission approved the "approval on the registration of guangdong yiduoli biotechnology co., ltd. to issue shares to specific objects" (securities regulatory license [2020] no. 2498), and the company issued 10,152,284 common shares to specific objects, raising a total of rmb 100 million. after deducting the underwriting and sponsorship fees and other expenses totaling rmb 2.6588 million, the net amount of funds raised was rmb 97.3412 million. the above funds were in place on october 23, 2020. the issuance price of this fixed increase is rmb 9.85 per share.